- Home
- SLND vs SPRO Comparison
SLND vs SPRO Comparison
Compare SLND & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- SPRO
- Stock Information
- Founded
- SLND 1900
- SPRO 2013
- Country
- SLND United States
- SPRO United States
- Employees
- SLND N/A
- SPRO N/A
- Industry
- SLND Military/Government/Technical
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- SLND Industrials
- SPRO Health Care
- Exchange
- SLND Nasdaq
- SPRO Nasdaq
- Market Cap
- SLND 175.8M
- SPRO 164.4M
- IPO Year
- SLND N/A
- SPRO 2017
- Fundamental
- Price
- SLND $4.49
- SPRO $2.91
- Analyst Decision
- SLND Strong Buy
- SPRO Buy
- Analyst Count
- SLND 1
- SPRO 4
- Target Price
- SLND $5.00
- SPRO $5.00
- AVG Volume (30 Days)
- SLND 72.5K
- SPRO 1.6M
- Earning Date
- SLND 08-11-2025
- SPRO 08-04-2025
- Dividend Yield
- SLND N/A
- SPRO N/A
- EPS Growth
- SLND N/A
- SPRO N/A
- EPS
- SLND N/A
- SPRO N/A
- Revenue
- SLND $931,568,000.00
- SPRO $44,584,000.00
- Revenue This Year
- SLND $3.76
- SPRO N/A
- Revenue Next Year
- SLND $1.08
- SPRO N/A
- P/E Ratio
- SLND N/A
- SPRO N/A
- Revenue Growth
- SLND N/A
- SPRO N/A
- 52 Week Low
- SLND $1.85
- SPRO $0.51
- 52 Week High
- SLND $4.67
- SPRO $3.09
- Technical
- Relative Strength Index (RSI)
- SLND 71.29
- SPRO 71.31
- Support Level
- SLND $3.66
- SPRO $2.79
- Resistance Level
- SLND $4.62
- SPRO $3.03
- Average True Range (ATR)
- SLND 0.26
- SPRO 0.12
- MACD
- SLND 0.05
- SPRO -0.08
- Stochastic Oscillator
- SLND 87.04
- SPRO 40.63
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.